Obstetric Anesthesia Problems
Conditions
Keywords
Anesthesia, Obstetric, fluid therapy, cesarean section, spinal anesthesia
Brief summary
Whether the usage of non-invasive arterial blood pressure monitor to guide fluid therapy in caesarean section can effectively reduce the incidence of hypotension and fetal complications.
Detailed description
Spinal anesthesia in the cesarean section often causes significant peripheral vascular dilatation, decreases blood pressure and cardiac output reduction which leads to maternal nausea, vomiting, dizziness and uteroplacental hypoperfusion. Infusion therapy and the use of vasopressor can prevent and treat the incidence of hypotension. Appropriate fluid therapy can not only maintain maternal tissue perfusion, but also reduce uteroplacental hypoperfusion. In the present study, perioperative goal directed fluid therapy is used. The non-invasive continuous hemodynamic monitor is used in this study, and the parameters (blood pressure (BP), stroke volume(SV), stroke volume variation (SVV), cardiac output (CO)) are used to determine the parameters of the blood transfusion in cesarean section as infusion guidelines. The application of Clearsight system to the pre-infusion of target-guided crystalloid solution is compared with the infusion of quantitative crystalline solution in the hope of reducing the incidence of maternal hypotension, reducing the use of vasopressin, improving uteroplacental perfusion and reducing the incidence of fetal acidosis.
Interventions
Goal directed Fluid therapy: Within 30 minutes before spinal anaesthesia, repeat Ringer's Injection 3ml/kg within 3 minutes with 1-min gap until ΔSV\<5%
Inject marcaine and fentanyl to CSF for anaesthesia
Sponsors
Study design
Eligibility
Inclusion criteria
1. 20-45 y/o parturient 2. Receive spinal anesthesia (SA) or combined spinal-epidural anesthesia (CSA) to undergo cesarean section
Exclusion criteria
1. Emergent C/S 2. BMI\>35kg/m2 3. Height \<150cm or \>175 cm 4. Patients with major cardiovascular disease, preeclampsia or eclampsia. 5. Gestational age \< 36wks 6. Multiple pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of maternal hypotension | delivery |
Secondary
| Measure | Time frame |
|---|---|
| Total fluid volume | delivery |
| Dosage of vasopressor | delivery |
Countries
Taiwan